NCT01600781

Brief Summary

This is a randomised, controlled, open-label intervention study. It is hypothesized that supplementation with a fibre enriched sip feed will improve the nutritional status, gut microbiota and quality of life (QOL) of children with acute lymphoblastic leukemia, and may enhance their immune response. This could give them a better chance to finish their induction chemotherapy successfully with fewer side effects.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Dec 2011

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2011

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

May 15, 2012

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 17, 2012

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2014

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2014

Completed
Last Updated

February 10, 2015

Status Verified

February 1, 2015

Enrollment Period

2.7 years

First QC Date

May 15, 2012

Last Update Submit

February 8, 2015

Conditions

Keywords

Improve the nutritional statusQOLchildrenenhance immune responseinduction chemotherapyfewer side effects

Outcome Measures

Primary Outcomes (1)

  • Study Parameters

    Primary * Change in body weight between Baseline and Day 42 \[kg, weight-for-age z score, weight-for-height z-score\] * Percentage of children with body weight loss between Baseline and Day 42 \[%\]

    42 days

Secondary Outcomes (1)

  • Study Parameters

    from day 1 to day 91 of the study

Study Arms (2)

NutriniDrink/Fortini group

ACTIVE COMPARATOR

this group will receive 2 bottles of NutriniDrink/Fortini MF unflavoured daily (200 ml each) and standard dietary counselling for a period of 6 weeks.

Dietary Supplement: NutriniDrink/Fortini MF unflavoured (1.5kcal/ml)

control group

NO INTERVENTION

this control group will only receive standard dietary counselling

Interventions

During the 6-week Intervention period children allocated to group 1 will consume 2 bottles of study product per day (400ml in total).

NutriniDrink/Fortini group

Eligibility Criteria

Age2 Years - 12 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Age should be above 2 years and children should be pre-pubertal.
  • Hospitalized for the entire (6 week) intervention period.
  • About to receive? induction chemotherapy.
  • Able to tolerate oral feeding.
  • Written informed consent from parents/guardian (and child, if applicable to local law).

You may not qualify if:

  • ALL patients \< 2 years and those who show signs of puberty.
  • ALL patients who cannot tolerate oral feeding and/or are on parenteral nutrition.
  • ALL patients with a known history of cow's milk allergy/intolerance or galactosemia.
  • ALL patients requiring a fibre-free diet.
  • Investigator's uncertainty about the willingness or ability of the child/carer to comply with the protocol requirements.
  • Participation in any other study involving investigational or marketed products concomitantly or within two weeks prior to entry into the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Children's cancer Hospital Egypt-57357

Cairo, 11441, Egypt

Location

MeSH Terms

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Condition Hierarchy (Ancestors)

Leukemia, LymphoidLeukemiaNeoplasms by Histologic TypeNeoplasmsHematologic DiseasesHemic and Lymphatic DiseasesLymphoproliferative DisordersLymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Study Officials

  • Alaa El-Hadad, PhD

    Children's Cancer Hospita Egypt-57357

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 15, 2012

First Posted

May 17, 2012

Study Start

December 1, 2011

Primary Completion

August 1, 2014

Study Completion

September 1, 2014

Last Updated

February 10, 2015

Record last verified: 2015-02

Locations